We now demonstrate that PGE2 inhibits IFN-γ induced CXCL9 and CXCL10 secretion from breast cancer cells and that, conversely, the COX inhibitors acetylsalicylic acid (ASA) and indomethacin augment this release. This evidence concerns the gene CXCL10 and breast cancer.